Rigel Pharmaceuticals, Inc. (RIGL) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
3.95
↓-56% vs avg
5yr avg: 8.90
30Y Low6.4·High11.4
P/FCF
↓
6.51
↓-82% vs avg
5yr avg: 35.43
30Y Low9.6·High91.6
P/B Ratio
↓
1.28
↓-96% vs avg
5yr avg: 35.81
30Y Low1.2·High90.5
ROE
↑
185.9%
↓+2113% vs avg
5yr avg: -9.2%
30Y Low-142%·High186%
Debt/EBITDA
↓
0.42
↓-69% vs avg
5yr avg: 1.34
30Y Low0.0·High2.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RIGL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Rigel Pharmaceuticals, Inc. trades at 1.4x earnings, 86% below its 5-year average of 9.6x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a discount of 94%. On a free-cash-flow basis, the stock trades at 6.5x P/FCF, 82% below the 5-year average of 35.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $493M | $807M | $297M | $252M | $259M | $452M | $591M | $358M | $369M | $490M | $225M |
| Enterprise Value | $506M | $820M | $301M | $280M | $276M | $463M | $599M | $372M | $293M | $452M | $210M |
| P/E Ratio → | 1.37 | 2.20 | 16.99 | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.67 | 2.74 | 1.66 | 2.16 | 2.15 | 3.03 | 5.44 | 6.04 | 8.30 | 109.30 | 11.02 |
| P/B Ratio | 1.28 | 2.06 | 90.48 | — | — | 14.87 | 17.36 | 6.66 | 3.36 | 4.87 | 4.08 |
| P/FCF | 6.51 | 10.67 | 9.57 | — | — | 86.04 | — | — | — | — | — |
| P/OCF | 6.51 | 10.67 | 9.45 | — | — | 76.86 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RIGL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Rigel Pharmaceuticals, Inc.'s enterprise value stands at 4.0x EBITDA, 56% below its 5-year average of 8.9x. The Healthcare sector median is 14.1x, placing the stock at a 72% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.79 | 1.68 | 2.40 | 2.29 | 3.11 | 5.52 | 6.27 | 6.58 | 100.83 | 10.33 |
| EV / EBITDA | 3.95 | 6.41 | 11.38 | — | — | — | — | — | — | — | — |
| EV / EBIT | 4.03 | 6.53 | 11.44 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 10.83 | 9.68 | — | — | 88.26 | — | — | — | — | — |
RIGL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Rigel Pharmaceuticals, Inc. earns an operating margin of 42.6%. Operating margins have expanded from -17.5% to 42.6% over the past 3 years, signaling improving operational efficiency. Return on equity of 185.9% is exceptionally high, though this is partly amplified by negative book value driven by aggressive share buybacks. ROIC of 45.8% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.3% | 93.3% | 89.6% | 93.9% | 98.5% | 99.3% | 99.2% | 98.5% | 99.4% | -931.9% | -211.3% |
| Operating Margin | 42.6% | 42.6% | 13.5% | -17.5% | -46.2% | -8.4% | -26.7% | -116.5% | -163.3% | -1775.6% | -342.2% |
| Net Profit Margin | 124.7% | 124.7% | 9.8% | -21.5% | -48.7% | -12.0% | -27.4% | -112.2% | -158.3% | -1739.3% | -339.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 185.9% | 185.9% | 531.8% | — | -699.0% | -55.6% | -67.7% | -81.3% | -67.0% | -100.2% | -94.6% |
| ROA | 108.3% | 108.3% | 12.4% | -20.0% | -38.8% | -12.9% | -23.1% | -46.4% | -54.6% | -79.1% | -66.0% |
| ROIC | 45.8% | 45.8% | 641.6% | -1170.0% | -183.0% | -22.1% | -39.4% | -102.4% | -113.3% | -115.4% | -109.8% |
| ROCE | 48.7% | 48.7% | 29.4% | -30.8% | -64.3% | -14.4% | -36.5% | -68.8% | -68.5% | -101.9% | -90.9% |
RIGL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Rigel Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 0.4x, which is very conservative (87% below the sector average of 3.1x). Net debt stands at $13M ($53M total debt minus $41M cash). Interest coverage of 17.1x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.14 | 0.14 | 18.24 | — | — | 1.01 | 1.15 | 0.67 | — | 0.00 | 0.06 |
| Debt / EBITDA | 0.42 | 0.42 | 2.27 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.03 | 0.98 | — | — | 0.38 | 0.26 | 0.26 | -0.69 | -0.38 | -0.26 |
| Net Debt / EBITDA | 0.10 | 0.10 | 0.12 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 0.17 | 0.10 | — | — | 2.22 | — | — | — | — | — |
| Interest Coverage | 17.14 | 17.14 | 3.32 | -2.65 | -14.80 | -2.56 | -20.98 | -198.68 | — | — | — |
RIGL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Rigel Pharmaceuticals, Inc.'s current ratio of 2.42x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.86x to 2.42x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.42 | 2.42 | 2.13 | 1.86 | 1.78 | 2.43 | 2.18 | 2.04 | 4.94 | 6.40 | 3.37 |
| Quick Ratio | 2.30 | 2.30 | 2.04 | 1.76 | 1.64 | 2.33 | 2.14 | 2.02 | 4.91 | 6.40 | 3.37 |
| Cash Ratio | 1.56 | 1.56 | 1.22 | 1.07 | 0.89 | 1.97 | 1.40 | 1.68 | 4.63 | 6.31 | 3.31 |
| Asset Turnover | — | 0.57 | 1.09 | 1.00 | 0.90 | 0.89 | 0.98 | 0.40 | 0.32 | 0.04 | 0.26 |
| Inventory Turnover | 1.71 | 1.71 | 3.11 | 1.29 | 0.19 | 0.16 | 0.55 | 0.67 | 0.32 | — | — |
| Days Sales Outstanding | — | 64.20 | 84.73 | 95.40 | 122.39 | 37.84 | 53.67 | 62.25 | 33.43 | — | — |
RIGL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Rigel Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 73.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 73.0% | 45.5% | 5.9% | — | — | — | — | — | — | — | — |
| FCF Yield | 15.4% | 9.4% | 10.4% | — | — | 1.2% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 3.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 3.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $19M | $18M | $17M | $17M | $17M | $17M | $17M | $16M | $13M | $9M |
Peer Comparison
Compare RIGL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RIGLYou | $493M | 1.4 | 4.0 | 6.5 | 93.3% | 42.6% | 185.9% | 45.8% | 0.4 |
 PRTA | $602M | -2.5 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 FOLD | $4B | -80.5 | 140.6 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
 RARE | $3B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 HALO | $8B | 25.9 | 8.5 | 12.1 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 PTCT | $6B | 8.6 | 5.6 | 7.9 | 95.9% | 49.5% | — | — | 0.5 |
 ACAD | $4B | 15.8 | 13.6 | 23.1 | 91.5% | 24.1% | 38.9% | 45.2% | 0.2 |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 ARQT | $3B | -185.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 CABA | $381M | -2.3 | — | — | — | — | -127.0% | -429.6% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
See RIGL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RIGL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RIGL vs PRTA
Side-by-side business, growth, and profitability comparison vs Prothena Corporation plc.
Start ComparisonRIGL — Frequently Asked Questions
Quick answers to the most common questions about buying RIGL stock.
What is Rigel Pharmaceuticals, Inc.'s P/E ratio?
Rigel Pharmaceuticals, Inc.'s current P/E ratio is 1.4x. The historical average is 41.3x.
What is Rigel Pharmaceuticals, Inc.'s EV/EBITDA?
Rigel Pharmaceuticals, Inc.'s current EV/EBITDA is 4.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 8.9x.
What is Rigel Pharmaceuticals, Inc.'s ROE?
Rigel Pharmaceuticals, Inc.'s return on equity (ROE) is 185.9%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -62.9%.
Is RIGL stock overvalued?
Based on historical data, Rigel Pharmaceuticals, Inc. is trading at a P/E of 1.4x. Compare with industry peers and growth rates for a complete picture.
What are Rigel Pharmaceuticals, Inc.'s profit margins?
Rigel Pharmaceuticals, Inc. has 93.3% gross margin and 42.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Rigel Pharmaceuticals, Inc. have?
Rigel Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 0.4x, indicating low leverage. A ratio below 2x is generally considered financially healthy.